Lanreotide Acetate (CAS 127984-74-1) – Wholesale & Research Grade
Lanreotide Acetate, a synthetic analogue of somatostatin, has gained prominence in the medical and research communities for its multifaceted applications, particularly in the management of neuroendocrine tumors and acromegaly. This compound, often referred to as Lanreotide or Somatuline, acts primarily by inhibiting the secretion of growth hormone and insulin, thereby playing a crucial role in controlling the growth of tumors and alleviating symptoms associated with hormone-secreting tumors.
Research Applications
The clinical applications of Lanreotide Acetate extend beyond acromegaly treatment. It has shown efficacy in neuroendocrine tumors, particularly gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Researchers are also exploring its role in the management of conditions such as carcinoid syndrome, where it helps mitigate flushing and diarrhea. Furthermore, ongoing studies are investigating its potential applications in other malignancies, emphasizing its versatility in oncology.
Mechanism of Action
Lanreotide Acetate functions through a unique mechanism by mimicking the effects of natural somatostatin, binding to somatostatin receptors (SSTRs) on tumor cells. This binding inhibits the secretion of various hormones and growth factors, leading to decreased cell proliferation and tumor growth. Its selective action on different somatostatin receptor subtypes offers a targeted therapeutic approach, making it a valuable asset in cancer treatment.
Solubility and Storage Advice
Lanreotide Acetate is soluble in aqueous solutions, making it suitable for various pharmaceutical formulations. For optimal stability, it should be stored at controlled room temperatures, away from direct light and moisture. It is crucial to follow specific storage guidelines to maintain its efficacy, particularly in clinical settings.
Future Research Directions
- Investigating the combination of Lanreotide with other therapies to enhance treatment outcomes.
- Exploring its potential benefits in other hormone-related conditions and cancers.
- Developing novel formulations to improve bioavailability and patient compliance.
As research continues, Lanreotide Acetate remains a key focus area within endocrinology and oncology, promising new insights and therapeutic strategies for complex medical conditions.
| CAS Number | 127984-74-1 |
|---|---|
| Formula | C56H73N11O12S2 |
| Mol. Weight | 1156.4 g/mol |
| IUPAC Name | acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hy... |
| Grade | HPLC ≥98% |
Synthesis & Storage
Lanreotide Acetate is supplied as a lyophilized powder to ensure stability during transit.
For long-term storage of CAS 127984-74-1, we recommend maintaining at -20°C.
Researchers must reconstitute this peptide with bacteriostatic water or sterile solvent only when ready for use.
Quality Control: All batches undergo rigorous HPLC purity testing (≥98%) prior to dispatch from our USA fulfillment center.